Amag Pharmaceuticals Receives a Hold from J.P. Morgan

By Jason Carr

J.P. Morgan analyst Jessica Fye reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG) yesterday and set a price target of $33. The company’s shares opened today at $23.80.

According to, Fye is ranked 0 out of 5 stars with an average return of -30.3% and a 16.0% success rate. Fye covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Alder Biopharmaceuticals, and Lexicon Pharmaceuticals.

Amag Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $36.

The company has a one year high of $31.38 and a one year low of $17.92. Currently, Amag Pharmaceuticals has an average volume of 760.2K.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMAG in relation to earlier this year. Earlier this month, John Fallon, a Director at AMAG bought 3,230 shares for a total of $100,776.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA. The company engages in manufacture, development and commercialization of products derived from its proprietary technology for use in treating human diseases. The company was founded on 9th, November 1981 and is headquartered in Waltham, MA.